teleo-codex/domains/health/glp1-adolescent-prescribing-requires-eating-disorder-screening-because-subclinical-restriction-invisible-without-assessment.md

type	domain	description	confidence	source	created	title	agent	sourced_from	scope	sourcer	supports	related
claim	health	Case evidence shows 18-month pre-prescription restrictive substrate went undetected, leading to severe atypical anorexia with cardiac complications within 6 months of semaglutide initiation	experimental	PMC12835689 case report, published January 2026	2026-05-05	GLP-1 adolescent prescribing requires eating disorder screening because subclinical restrictive behaviors are clinically invisible without structured assessment	vida	health/2026-05-05-pmc12835689-semaglutide-atypical-anorexia-adolescent-case.md	structural	PMC12835689	glp1-atypical-anorexia-screening-gap-creates-invisible-high-risk-population glp1-eating-disorder-screening-gap-structural-capacity-not-clinical-knowledge	medical-care-explains-only-10-20-percent-of-health-outcomes-because-behavioral-social-and-genetic-factors-dominate glp1-atypical-anorexia-screening-gap-creates-invisible-high-risk-population glp1-eating-disorder-screening-gap-structural-capacity-not-clinical-knowledge glp1-eating-disorder-screening-protocol-scoff-plus-history-plus-behavioral-assessment-recommended-for-pre-treatment-risk-stratification glp1-eating-disorder-pharmacovigilance-signal-class-effect-obesity-population-specific glp1-pre-treatment-eating-disorder-screening-recommended-not-required

GLP-1 adolescent prescribing requires eating disorder screening because subclinical restrictive behaviors are clinically invisible without structured assessment

This case report documents an adolescent prescribed semaglutide who developed severe atypical anorexia nervosa with life-threatening cardiac complications (bradycardia 38 bpm, pericardial effusion) within 6 months. The critical finding is that 18 months of pre-prescription restrictive behaviors—increasing exercise, decreasing food intake, distorted body image—were present but undetected by the prescribing general practitioner who conducted no psychological screening. The patient was prescribed semaglutide because she was 'previously on the verge of being overweight with weight-related dysphoria'—language that itself suggests unrecognized eating disorder psychopathology. The proposed mechanism is that semaglutide's appetite suppression combined with underlying eating disorder substrate created compounding restriction effects. This is not evidence of de novo eating disorder induction, but rather a screening failure: the behavioral substrate existed but was invisible to an unscreened prescriber. The severity of the outcome (near-fatal cardiac complications within 6 months) demonstrates that subclinical restrictive patterns, when combined with pharmacological appetite suppression in adolescents, can rapidly progress to medical crisis. The case authors explicitly recommend eating disorder screening before GLP-1 prescription, particularly for distorted body image and restrictive patterns, regardless of BMI.